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Background and Aims: Oncostatin M (OSM) signaling is implicated in atherosclerosis,
however themechanism remains unclear. We investigated the impact of common genetic
variants inOSM and its receptors,OSMR and LIFR, on overall plaque vulnerability, plaque
phenotype, intraplaque OSMR and LIFR expression, coronary artery calcification burden
and cardiovascular disease susceptibility.
Methods and Results: We queried Genotype-Tissue Expression data and found
that rs13168867 (C allele) was associated with decreased OSMR expression and that
rs10491509 (A allele) was associated with increased LIFR expression in arterial tissues.
No variant was significantly associated with OSM expression.
We associated these two variants with plaque characteristics from 1,443 genotyped
carotid endarterectomy patients in the Athero-Express Biobank Study. After correction
for multiple testing, rs13168867 was significantly associated with an increased
overall plaque vulnerability (β = 0.118 ± s.e. = 0.040, p = 3.00 × 10−3, C
allele). Looking at individual plaque characteristics, rs13168867 showed strongest
associations with intraplaque fat (β = 0.248 ± s.e. = 0.088, p = 4.66 × 10−3,
C allele) and collagen content (β = −0.259 ± s.e. = 0.095, p = 6.22 × 10−3, C
allele), but these associations were not significant after correction for multiple testing.
rs13168867 was not associated with intraplaque OSMR expression. Neither was
intraplaque OSMR expression associated with plaque vulnerability and no known OSMR
eQTLs were associated with coronary artery calcification burden, or cardiovascular
disease susceptibility. No associations were found for rs10491509 in the LIFR locus.
van Keulen et al. Genetics OSMR and Plaque Vulnerability
Conclusions: Our study suggests that rs1316887 in the OSMR locus is associated
with increased plaque vulnerability, but not with coronary calcification or cardiovascular
disease risk. It remains unclear through which precise biological mechanisms OSM
signaling exerts its effects on plaque morphology. However, the OSM-OSMR/LIFR
pathway is unlikely to be causally involved in lifetime cardiovascular disease susceptibility.
Keywords: cardiovascular disease, atherosclerosis, plaque, genetics, OSM, OSMR, LIFR
INTRODUCTION
The prevalence of cardiovascular disease (CVD) is high, poses
a significant global burden and is expected to rise (1). Arterial
inflammation, leading to asymmetric focal arterial thickening
and atherosclerotic plaque formation and progression, is
the primary mechanism underlying CVD (2). Inflammatory
cytokines contribute to arterial inflammation and subsequent
atherosclerotic plaque formation (3). One cytokine, for which
there is mounting evidence suggesting a role in atherosclerosis
development is OSM (4, 5). It has been shown that OSM
is present in both murine and human atherosclerotic plaques
(6). Moreover, murine studies showed that OSM receptor
(OSMR)−/−ApoE−/− mice have reduced plaque size and
improved plaque stability compared to their OSMR-expressing
littermates (7), indicating that OSM drives atherosclerosis
development. These observations are in line with our previous
work, in which we showed that simultaneous signaling of OSM
through OSMR and leukemia inhibitory factor receptor (LIFR),
induces activation in human endothelial cells, suggestive of a
role in atherosclerosis development (8). In contrast, chronic
OSM administration to APOE∗3Leiden.CETP mice reduces the
atherosclerotic lesion size and severity, and high circulating
OSM levels correlate with increased post-incident coronary heart
disease survival probability in humans (9).
Although all these studies implicate that OSM is involved in
atherosclerosis, little is known about the effects of OSMon plaque
composition in humans. Grouped in the interleukin 6 subfamily
of cytokines, OSM is released by activated immune cells (10–12),
and exerts pleiotropic effects on cell proliferation, inflammation,
hematopoiesis, tissue remodeling, and development (13). Its
signals are transduced through binding to either OSMR or LIFR,
which form a heterodimer with glycoprotein 130 (8, 14), that in
turn activatesmultiple pathways (14). It is suggested that the ratio
of the two receptor types expressed on the cell membrane is a
potential regulatory mechanism for the multiple, and sometimes
opposing, effects that are exerted by OSM (15).
Thus, given its pleiotropic function, it is difficult to predict
how OSM contributes to atherosclerotic plaque formation. Cell
andmurine studies have shown that OSM promotes angiogenesis
(4), endothelial activation (8), vessel permeability (16), and
osteoblastic differentiation (17). Therefore, increased OSM levels
hypothetically results in a higher intraplaquemicrovessel density,
intraplaque hemorrhages and plaque calcification, thereby
contributing to plaque destabilization (18, 19). In other cell
and murine studies, OSM promotes fibroblast proliferation (20),
collagen formation (20), smoothmuscle cell proliferation (6), and
M2macrophage polarization (21). These processes hypothetically
lead to enhanced fibrosis, and attenuated inflammation, thereby
contributing to plaque stabilization (22).
Large-scale studies have shown that cis-acting genetic variants
associated to gene expression [expression quantitative trait
loci (eQTLs) (23)] are key to disease susceptibility (24). This
means that gene expression in a given tissue differs between
individuals carrying different genotypes which ultimately results
in differential disease susceptibility. Thus, on the premise that
alleles are randomly distributed at conception and are invariant
throughout a lifetime, meaning that genetics is not influenced
by disease or risk factors, eQTLs can be used as proxies of
gene expression to examine the effect on plaque morphology
(25). We hypothesized that if circulating OSM, or arterial OSMR
or LIFR expression has an effect on plaque morphology, these
phenotypic differences will be observed among genotype groups
of the eQTL. We aimed to investigate the double-edged sword
of OSM signaling on the composition of human atherosclerotic




The Athero-Express Biobank Study (https://www.atheroexpress.
nl) is an ongoing prospective study, containing biomaterial
of patients elected for endarterectomy at two Dutch tertiary
referral centers. Details of the study design were described before
(26). Briefly, blood subfractions are obtained before and arterial
plaque material during endarterectomy. Each plaque is dissected
into segments of 0.5 cm. The culprit lesion is reserved for
histological assessment (see below), while surrounding segments
are immediately snap frozen in liquid nitrogen and stored
at −80◦C for later use, e.g., in order to perform RNA-seq
(see below). Only carotid endarterectomy (CEA) patients were
included in the present study. All research was conducted
according to the principles of the Declaration of Helsinki and its
later amendments, all patients provided informed consent and
the study was approved by the medical ethics committees.
Athero-Express Genotyping, Quality
Control, and Imputation
Details of genotyping were previously described (26). Briefly,
DNA was extracted from EDTA blood or (when no blood was
available) plaque samples of 1,858 consecutive patients from the
Athero-Express Biobank Study and genotyped in 2 batches. For
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the Athero-Express Genomics Study 1 (AEGS1), 836 patients,
included between 2002 and 2007, were genotyped using the
Affymetrix Genome-Wide Human SNP Array 5.0 (SNP5) chip
(Affymetrix Inc., Santa Clara, CA, USA). For the Athero-Express
Genomics Study 2 (AEGS2), 1,022 patients, included between
2002 and 2013 and not overlapping AEGS1, were genotyped
using the Affymetrix Axiom R© GW CEU 1 Array (AxM).
Both studies were carried out according to OECD standards.
After genotype calling, we adhered to community standard
quality control and assurance (QA/QA) procedures of the
genotype data from AEGS1 and AEGS2. Samples with low
average genotype calling and sex discrepancies (compared to
the clinical data available) were excluded. The data was further
filtered on (1) individual (sample) call rate >97%, (2) SNP call
rate >97%, (3) minor allele frequencies (MAF) >3%, (4) average
heterozygosity rate ± 3.0 s.d., (5) relatedness (pi-hat >0.20), (6)
Hardy–Weinberg Equilibrium (HWE p < 1.0 × 10−6), and (7)
population stratification (based on HapMap 2, release 22, b36)
by excluding samples deviating more than 6 standard deviations
from the average in five iterations during principal component
analysis (PCA) and by visual inspection as previously described
(26). After QA/QA, 657 samples and 403,789 SNPs in AEGS1,
and 869 samples and 535,983 SNPs in AEGS2 remained. To
correct for genetic ancestry and population stratification we
performed PCA in each cleaned dataset to obtain principal
components for downstream analyses as described before (26).
We used SHAPEIT2 (27) for phasing and finally the data was
imputed with 1000G phase 3 (28) and GoNL 5 (29) as a reference
on genome build 37. Note that we only selected the CEA patients
in these datasets, leaving 1,443 samples for our further analyses.
Variant Selection
We queried data from the Genotype-Tissue Expression (GTEx)
Portal (https://gtexportal.org) (23) for cis-acting variants [defined
as variants within 1Mb of a given gene (30)] that alter OSM
expression in whole blood, and OSMR or LIFR expression in
non-diseased arterial tissue. We selected common variants with
a MAF > 3%, which yielded two variants in total: rs13168867
for OSMR in tibial arterial tissue and rs10491509 for LIFR in
aortic arterial tissue. We found no eQTL for circulating OSM
expression, i.e., in whole blood. We harmonized the effect alleles
and effect sizes from these eQTLs to match the allele orientation
in the Athero-Express Biobank Study data.
Plaque Phenotyping
The (immuno)histochemical analysis of plaques have been
described previously (26, 31, 32). Briefly, per plaque, the culprit
lesion was identified directly after dissection, fixed in 4%
formaldehyde, embedded in paraffin and cut in 5µm sections on
a microtome for (immuno)histochemical analysis by pathology
experts. Calcification (hematoxylin & eosin, H&E) and collagen
content (picrosirius red) were semi-quantitatively scored and
defined as no/minor or moderate/heavy. Atheroma size (H&E
and picrosirius red) was defined as <10% or ≥10% fat content.
Macrophages (CD68) and smooth muscle cells (ACTA2) were
quantitatively scored and classified as percentage of plaque area.
Intraplaque hemorrhage (H&E) was defined as absent or present,
and vessel density was classified as the number of intraplaque
vessels (CD34) per 3–4 hotspots.
Plaque Vulnerability
Assessment of overall plaque vulnerability was performed
as previously described by Verhoeven et al. (25). Briefly,
macrophages and smooth muscle cells were semi-quantitatively
defined as no/minor or moderate/heavy. Each plaque
characteristic that defines a stable plaque (i.e., no/minor
macrophages, moderate/heavy collagen, moderate/heavy smooth
muscle cells and <10% fat) was given a score of 0, while each
plaque characteristic that defines a vulnerable plaque (i.e.,
moderate/heavy macrophages, no/minor collagen, no/minor
smooth muscle cells and ≥10% fat) was given a score of 1. The
score of each plaque characteristic was summed resulting in a
final plaque score ranging from 0 (most stable plaque) to 4 (most
vulnerable plaque). Intraobserver and interobserver variability
were examined previously and showed good concordance (κ =
0.6–0.9) (33).
Plaque Expression
Detailed information on the RNA sequencing (RNAseq)
experiment is described in the Supplemental Material.
In short, to assess the global expression profile, plaque
segments were thawed, cut up, and homogenized using ceramic
beads and tissue homogenizer (Precellys, Bertin instruments,
Montigny-le-Bretonneux, France), in the presence of TriPure
(Sigma Aldrich), and RNA was isolated according to TriPure
manufacturer’s protocol.
Library Preparation
was performed, adapting the CEL-Seq2 protocol for library
preparation (34, 35), as described before (36). The primer used
for initial reverse-transcription reaction was designed as follows:
an anchored polyT, a unique 6bp barcode, a unique molecular
identifier (UMI) of 6bp, the 5’ Illumina adapter and a T7
promoter, as described (36). Complementary DNA (cDNA) was
then used in the in vitro transcription (IVT) reaction (AM1334;
Thermo-Fisher). Amplified RNA (aRNA) was fragmented, and
cleaned, and RNA yield and quality in the suspension were
checked by Bioanalyzer (Agilent).
cDNA library construction was initiated according to
the manufacturer’s protocol, adding randomhexRT primer as
random primer. PCR amplification was done with Phusion
High-Fidelity PCR Master Mix with HF buffer (NEB, MA,
USA) and a unique indexed RNA PCR primer (Illumina) per
reaction. Library cDNA yield and quality were checked by Qubit
fluorometric quantification (Thermo-Fisher) and Bioanalyzer
(Agilent), respectively. Libraries were sequenced on the Illumina
Nextseq500 platform; paired end, 2× 75 bp.
Upon sequencing, retrieved fastq files were de-barcoded,
split into forward and reverse reads. Subsequently, these were
mapped making use of Burrows-Wheel aligner [BWA (37)]
version 0.7.17-r1188 and a cDNA reference (assembly hg19,
Ensembl release 84). Read counts and UMI counts were derived
from SAM files using custom perl code, and then gathered
into count matrices. Genes were annotated with Ensembl ID’s,
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and basic quality control was performed, encompassing filtering
out samples with low gene numbers (<10,000 genes), and read
numbers (<18,000 reads). These steps resulted in 641 samples
with up to 60,674 genes (Ensembl ID’s), and median of 178,626
reads per sample.
Data Analysis
Plaque vulnerability scores, and genotypes for rs10491509
and rs13168867, were added to metadata, upon which
this was combined with counts and annotation in a
SummarizedExperiment object (38). Counts were normalized
and transformed making use of the variance stabilization
transformation function (vst()) in DESeq2 (39). This results
in transformed data on a log2-scale, normalized for library
size, for visualization and ordination purposes. Differential
expression analysis between plaque vulnerability scores or
genotypes, used as “condition variables” was performed using
the DESeq2-function DESeq() on the raw counts. In short, three
steps are performed: 1. estimation of size factors, controlling
for sequencing depth; 2. estimation of dispersion values, that
capture variation around expected values. These expected values
take into account sequencing depth and differences caused by
variables in the design formula argument, i.e., “design = ∼
condition” where condition is a variable that specifies which
group samples belong to; and 3. fitting a generalized linear
model using the above-mentioned size factors and dispersion
values, estimating log fold changes. This results in a results table,
showing estimated log2 fold changes and p-values comparing
between two levels of the condition variable. Complete details for
statistical procedures used by the DESeq function are described
elsewhere (39).
Genetic Analyses
Quantitatively scored characteristics (macrophages, smooth
muscle cells, and the vessel density) were Box-Cox transformed
(40) to obtain a normal distribution. For genetic analyses we used
GWASToolKit (https://swvanderlaan.github.io/GWASToolKit/)
which is a wrap-around collection of scripts for SNPTEST (41).
Continuous and categorical variables were tested using linear
and logistic regression models, respectively. Models for genetic
analyses were corrected for age, sex, genotyping chip, and genetic
ancestry using principal components 1 through 4. Thus, the
models were of the form
phenotype∼ SNP+ age+ sex+ genotypingchip+ PC 1
+PC 2+ PC 3+ PC 4.
Multiple Testing and Power
Correction for multiple testing resulted in a corrected p-value
of p = 0.05/[(7 plaque phenotypes + plaque vulnerability) × 2
common variants] = 3.13 × 10−3. The power of the study was
estimated at±75% based on a sample size of 1,443, a minor allele
frequency (MAF) of 0.409 and a relative risk of 1.28 (http://csg.
sph.umich.edu/abecasis/cats/gas_power_calculator/).
TABLE 1 | Baseline characteristics of genotyped CEA patients from the
Athero-Express Biobank Study.
Patient characteristics Missing data (%)
Sex, male, n (%) 976 (64.0) 5.7
Age in years, mean (SD) 68.84 (9.33) 5.7
History
Cerebrovascular disease, n (%) 478 (33.2) 5.7
Coronary artery disease, n (%) 430 (29.9) 5.8
Peripheral artery disease, n (%) 297 (20.7) 5.8
Risk factors
Type 2 diabetes mellitus, n (%) 332 (23.1) 5.7
Hypertension, n (%) 1,017 (73.0) 8.7
Current smoker, n (%) 492 (34.9) 7.5
BMI, median (IQR) 26.0 (24.0–28.4) 11.5
eGFR, median (IQR) 72.3 (58.7–85.4) 8.1
Total cholesterol in mmol/L, median (IQR) 4.38 (3.60–5.25) 22.8
LDL in mmol/L, median (IQR) 2.40 (1.81–3.13) 27.8
HDL in mmol/L, median (IQR) 1.06 (0.87–1.30) 25.0
Triglycerides in mmol/L, median (IQR) 1.50 (1.08–2.04) 24.6
Medication
Anti-hypertensives, n (%) 1,110 (77.2) 5.8
Lipid lowering drugs, n (%) 1,112 (77.4) 5.8
Anti-thrombotics, n (%) 1,272 (88.6) 6.0
Symptoms
Asymptomatics, n (%) 195 (13.6) 6.0
Ocular, n (%) 221 (15.4) 6.0
TIA, n (%) 634 (44.2) 6.0
Stroke, n (%) 384 (26.8) 6.0
Cerebrovascular disease history is defined by ischemic stroke prior to surgery. Coronary
artery disease history includes diagnosed coronary artery disease, myocardial infarction,
percutaneous coronary intervention, and coronary artery bypass grafting. Peripheral
disease history includes diagnosed peripheral arterial occlusive disease, femoral artery
interventions, and ankle-brachial index <70. Type 2 diabetes mellitus includes all
individuals with diagnosed type 2 diabetes mellitus and those on appropriate medication.
Hypertension includes all individuals with self-reported hypertension. Current smokers
include all individuals smoking up to 6 months until the surgery date. BMI, kg/m2. eGFR
rate was based on the Modification of Diet in Renal Disease formula, mL/min/1.73
m2. Anti-hypertensives include all anti-hypertension medication. Anti-thrombotics include
clopidogrel, dipyridamole, acenocoumarol, ascal, and other anti-platelet drugs. Missing
data shows the percentage of the patients of which we lack information on the specific
patient characteristic.
Data and Scripts




Common Variants Altering OSM, OSMR,
and LIFR Expression
We included and genotyped 1,443 carotid endarterectomy
patients in this study. We combined these groups (Table 1)
for overall plaque vulnerability and phenotype analyses,
as we previously showed that the baseline characteristics
between the two genotyping groups (AEGS1 and AEGS2) are
comparable (26).
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FIGURE 1 | Association of OSMR and LIFR variants in non-diseased arterial tissues. Per variant, the normalized expression of OSMR (A) and LIFR (B) is given in
non-diseased arterial tissue. Data from GTEx Portal (www.gtexportal.org). NES: Normalized effect size. In aortic arterial tissue, rs13168867 had a NES of −0.123 and
in tibial arterial tissue, rs10491509 had a NES of 0.0881 (Supplementary Figures 1, 2).
OSM is secreted by, among others, neutrophils (12),
monocytes (11), macrophages (11) and T-cells (10), and
acts through binding to OSMR and LIFR (14, 42, 43) in
the arterial wall (7, 44). Thus, we queried data from the
Genotype-Tissue Expression project (GTEx) (23) for SNPs
that alter OSM expression in whole blood and LIFR and
OSMR expression in arterial tissue. There were no significant
eQTLs for OSM, but there were two eQTLs associated with
altered OSMR (rs13168867) or LIFR (rs10491509) expression
in arterial tissue. The C allele of rs13168867 is associated with
decreased OSMR expression in the tibial artery (Figure 1A),
and the A allele of rs10491509 is associated with increased
LIFR expression in the aortic artery (Figure 1B). Cross-tissue
meta-analysis showed that these variants have m-values >0.9
in both tibial and aortic artery tissue, indicating a high
posterior probability that they are single cis-eQTLs in both
tissues (Supplementary Figures 1, 2).
Genetic Association With Plaque
Vulnerability
To determine the effect of OSM signaling on the overall plaque
vulnerability, we correlated the rs13168867 and rs10491509
genotypes to the overall plaque vulnerability, which was
given a score ranging from 0 (least vulnerable plaque) to
4 (most vulnerable plaque). The effect allele of variant
rs13168867 in the OSMR locus was significantly correlated
with an increased overall plaque vulnerability (β = 0.118
± s.e. = 0.040 (C allele), p = 3.00 × 10−3, Figure 2).
No association was observed with rs10491509 and overall
plaque vulnerability.
Genetic Association With Plaque
Phenotypes
To determine the effect of OSM signaling on the individual
plaque characteristics comprising the overall plaque
vulnerability, we assessed the association between rs13168867
and rs10491509 and seven plaque phenotypes in the Athero-
Express Biobank Study. Although not significant after correction
for multiple testing, the strongest associations were observed
between the effect allele of variant rs13168867 in theOSMR locus
and intraplaque fat (β = 0.248 ± s.e. = 0.088 (C allele), p = 4.66
× 10−3), and collagen content (β = −0.259 ± s.e. = 0.095 (C
allele), p= 6.22× 10−3, Table 2). No associations were observed
between rs10491509 and any of the plaque phenotypes.
Known eQTLs of OSMR and LIFR
Expression in Non-diseased Arterial Tissue
Are Not Associated With Expression in
Atherosclerotic Plaques
Atherosclerotic disease progression changes the artery-specific
transcriptional dynamics, and may therefore abolish the effects
of known OSMR and LIFR eQTLs in non-atherosclerotic arterial
tissues. Thus, we tested whether these eQTLs were associated
with OSMR and LIFR expression in carotid atherosclerotic
plaques. Neither variant showed associations with expression of
OSM, OSMR, and LIFR (Supplementary Table 1).
Intraplaque OSMR Expression Is Not
Associated With Plaque Vulnerability
As rs13168867 was associated with an increased overall
plaque vulnerability, we next investigated if intraplaque OSMR
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FIGURE 2 | Association of OSMR and LIFR variants with overall plaque vulnerability. The plaques were given a vulnerability score ranging from 0 (least vulnerable) to 4
(most vulnerable). The bars represent the proportion of each plaque score per genotype for rs13168867 in the OSMR locus (A) and rs10491509 in the LIFR locus (B).
The table shows the results from GTEx Portal (23) where Gene is the gene of interest; Variant is the eQTL as found in GTEx Portal, and NES refers to the normalized
effect size on expression from GTEx Portal. The Alleles refer to the effect allele and the other allele in both GTEx Portal and the Athero-Express Biobank. The remaining
columns in the table are referring to the analysis of these eQTLs with respect to plaque vulnerability in the Athero-Express Biobank Study. Here EAF represents effect
allele frequency; Info refers to the estimated imputation score. The effect size (β) and standard error (s.e.) are relative to the effect allele; p indicates the p-value of
association with plaque vulnerability of the given eQTL; Bold p: p-value of association surpasses significance threshold (p < 3.13 × 10−3).
expression levels associated with overall plaque vulnerability.
Differential expression analyses, comparing the reference score
(0) with each increasing vulnerability score (1, 2, 3, or 4)
showed no associations between OSMR plaque expression
levels and plaque vulnerability (Supplementary Table 2). Neither
did intraplaque OSM or LIFR expression associate with
plaque severity.
Known eQTLs of OSMR and LIFR Do Not
Associate With Cardiovascular Diseases
The Athero-Express comprises patients with advanced stage
atherosclerotic plaques. Therefore, we assessed the effect of
known OSMR and LIFR eQTLs on coronary calcification
(CAC) as intermediate phenotype of atherosclerotic burden, and
primary cardiovascular outcomes as clinical manifestation. We
queried summary statistics from GWAS on CAC (n = 2,674)
(45), coronary artery disease (CAD, n = 336,755) (45, 46), and
ischemic stroke subtypes (sample sizes 242,573–522,258) (45–
47). Neither eQTL associated with increased CAC burden, or
cardiovascular disease susceptibility (Supplementary Table 3).
DISCUSSION
We investigated whether common variants associated to gene
expression, i.e., eQTLs, near OSM, OSMR and LIFR affect overall
plaque vulnerability and phenotype. We showed that one cis-
acting eQTL (rs13168867, C/T), of which the C allele associates
with reduced OSMR expression in non-diseased arterial tissue,
significantly associates with increased plaque vulnerability after
correction for multiple testing. This suggests that a decrease
in OSMR expression and therefore possibly a decrease in OSM
signaling, increases the chance of developing a vulnerable plaque.
To gain further insight into the role of genetically decreased
OSMR expression on developing a vulnerable plaque, we
examined the effect of rs13168867 on individual plaque
characteristics in more detail. The strongest associations were
found for rs13168867 with increased intraplaque fat and
decreased collagen content, suggesting that reduced OSM
signaling results in a larger lipid core and less fibrosis - in
line with a more vulnerable plaque phenotype. We previously
showed that OSM enhances intercellular adhesion molecule
(ICAM)-1 expression on human endothelial cells (8). Reduced
OSMR expression, which hypothetically results in reduced OSM
signaling, may therefore result in reduced ICAM-1 expression.
ICAM-1 depletion leads to M1 macrophage polarization (48),
which is the pro-inflammatory macrophage subtype that
promotes an unstable plaque phenotype (49). Reduced OSM
signaling could also explain the decreased collagen content as
OSM enhances in vitro fibroblast proliferation and collagen
formation (20). Moreover, it was previously shown that OSM
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TABLE 2 | OSMR and LIFR variants and their association with plaque phenotypes.
Gene Variant NES Alleles EAF Info Phenotype β (s.e.) p
OSMR rs13168867 −0.13 C/T 0.393 0.999 Calcification 0.036 (0.077) 0.637
Collagen −0.259 (0.095) 6.22 × 10−3
Fat content 0.248 (0.088) 4.66 × 10−3
Intraplaque hemorrhage −0.014 (0.080) 0.862
Smooth muscle cells 0.001 (0.011) 0.913
Vessel density −1.06 × 10−4 (0.004) 0.976
Macrophages 0.004 (0.015) 0.809
LIFR rs10491509 0.29 A/G 0.351 0.989 Calcification 0.046 (0.082) 0.577
Collagen 0.134 (0.104) 0.194
Fat content 0.086 (0.094) 0.363
Intraplaque hemorrhage 0.071 (0.086) 0.414
Smooth muscle cells −0.003 (0.012) 0.840
Vessel density 0.002 (0.004) 0.577
Macrophages 0.015 (0.016) 0.354
For each variant, the association with plaque phenotypes is given. NES: the normalized effect size on expression; Alleles: the effect allele and the other allele, respectively; EAF: effect
allele frequency in the Athero-Express Biobank; Info: estimated imputation score in the Athero-Express Biobank; β, effect size; s.e., standard error; p, p-value of association; Adj. p,
Bonferroni adjusted p-value. Calcification and collagen were classified as no/minor vs. moderate/heavy, fat content as 10 vs. >10% fat of plaque area, intraplaque hemorrhage was
classified as absent vs. present. Smooth muscle cells and macrophages were classified as Box-Cox transformed percentage of plaque area and vessel density as Box-Cox transformed
number of vessels/hotspot. None of the p-values surpassed significance threshold (3.13 × 10−3).
enhances liver fibrosis in mice (50) and that OSM is upregulated
in patients with pulmonary fibrosis (51). A reduction in OSM
signaling caused by decreased OSMR expression may therefore
result in decreased collagen content. Further studies are needed
to investigate these hypotheses.
A possible explanation for the lack of associations for
the variant (rs10491509) in the LIFR locus could be that an
increase in LIFR expression would not affect OSM signaling
as, hypothetically, there might already be a LIFR surplus
and therefore, an increase in LIFR expression will not affect
OSM signaling.
Although rs13168867 did associate with plaque vulnerability,
no associations were found between rs13168867 and intraplaque
OSMR expression, intraplaque OSMR expression and plaque
vulnerability, nor did rs13168867 associate with cardiovascular
disease outcomes. Possibly, OSM signaling mainly affects
atherogenesis and atherosclerosis development in the initial
phases of the disease. Arterial OSMR expression is reduced
in human atherosclerotic plaques when compared to normal
arteries9 and may therefore have bigger effects in the initial
phase, when OSMR expression is still high. Another possible
explanation is that OSM signaling may be overruled by for
example, other cytokines in later stages of the disease. Lastly,
although coronary thrombosis, and therefore cardiovascular
disease, is most often caused by plaque rupture, which is most
likely to happen in vulnerable plaques, thrombosis can also be
triggered by other processes, including plaque erosion and atrial
fibrillation (52, 53). Xie et al. showed that OSM is associated
with thrombosis in patients with atrial fibrillation and suggested
that OSM exerts thrombogenic effects by increasing tissue
factor expression and decreasing the expression of tissue factor
pathway inhibitors (53). So, OSM could potentially increase
the risk of cardiovascular disease through its thrombogenic
effects and at the same time decrease the risk of cardiovascular
disease by its atheroprotective effects. Potentially, the seemingly
atheroprotective effect of OSM that we described in our current
study may be neutralized by the thrombogenic or potential other
cardiovascular disease driving effects of OSM.
A limitation of association studies like ours, is that it is
challenging to uncover the biological meaning of the discovered
associations. It is likely that a reduction in OSMR expression
on the arterial wall reduces OSM signaling, but this is difficult
to verify. Firstly, OSM signaling is not only dependent on
OSMR, but also on the blood OSM levels. If there is no or little
OSM present in the blood, there might have been a surplus
of OSMR and in this case, there will be no change in OSM
signaling. Another possibility is that there is not only a decrease
of OSMR expression on the arterial wall, but also a decrease
in circulating OSMR levels, which can also bind to OSM and
acts as a neutralizer (54), also resulting in no net difference in
OSM signaling. Moreover, this study cannot make a distinction
between the timing and the duration of OSM signaling, which
may differentially affect atherosclerosis development as previous
studies have shown that OSM, like IL-6, can act differently in
the acute phase than in the chronic phase (8, 9, 55, 56). Finally,
we focused on only three genes (OSM, OSMR and LIFR), while
atherosclerosis is a multifactorial disease. Although studies like
ours can be very insightful to better understand the disease, single
variants seldomly show big correlations with disease outcome.
Compared to genome-wide association studies that include
thousands of individuals, the Athero-Express Biobank Study is
relatively small (n=1,443), and, given its design, finite in size.
However, it is well suited to examine the effect of common
disease-associated genetic variation on plaque morphology and
characteristics. Indeed, we estimated the power at ±75% given
a MAF=0.40 (approximately the frequency of rs13168867)
and relative risk = 1.28 (http://csg.sph.umich.edu/abecasis/gas_
power_calculator/).
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Recent developments in single-cell expression analyses might
extend on the present study by investigating which cell types,
that are present in the plaque, most abundantly express OSM,
OSMR and LIFR. Furthermore, it would be interesting to
investigate if the OSMR/LIFR expression ratio correlates with
plaque vulnerability and if this ratio might be a predictor of
plaque vulnerability.
CONCLUSION
Based on this work we conclude that the variant rs13168867 in
theOSMR locus is associated with increased plaque vulnerability,
but not with coronary calcification or cardiovascular disease
susceptibility. Given the multiple testing burden for individual
plaque characteristics, it remains unclear through which precise
biological mechanisms OSM signaling exerts its effects on
plaque morphology, although our data point toward lipid
metabolism and extracellular matrix remodeling. However, the
OSM-OSMR/LIFR pathway is unlikely to be causally involved
in lifetime cardiovascular disease susceptibility as none of the
investigated eQTLs associated with cardiovascular diseases.
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